abacavir

(redirected from Triumeq)
Also found in: Dictionary.
Related to Triumeq: Abacavir, Stribild

abacavir

 [ah-bak´ah-vir]
a non-nucleoside reverse transcriptase inhibitor used as an antiretroviral in treatment of human immunodeficiency virus infection; administered orally as the sulfate salt.

abacavir

/abac·a·vir/ (ah-bak´ah-vir) a nonnucleoside reverse transcriptase inhibitor used as the sulfate salt as an antiretroviral in the treatment of human immunodeficiency virus infection.

abacavir

(ə-băk′ə-vîr′)
n.
An antiviral drug, C14H18N6O, that is a nucleoside reverse transcriptor inhibitor and is used in its sulfate form in combination with other drugs for the treatment of HIV infection.

abacavir

an antiviral that is a nucleoside reverse transcriptase inhibitor.
indication It is prescribed in combination with other antiretroviral agents for HIV-1 infection.
contraindication Known hypersensitivity to this drug prohibits its use.
adverse effects Hypersensitivity reactions occur in approximately 5% of patients, and can be fatal. Other life-threatening adverse effects include granulocytopenia, anemia, and lactic acidosis. Common side effects include fever, headache, malaise, insomnia, nausea, vomiting, diarrhea, anorexia, and rash.

abacavir

An HIV-nucleoside reverse-transcriptase inhibitor (NRTI/integrase inhibitor) similar to AZT.
 
Adverse effects
Life-threatening allergic reactions—fever, dyspnea, rashes, intraoral blistering, nausea, headache.

abacavir

Ziagen, zintavir, 1592 AIDS An HIV nucleoside reverse transcriptase inhibitor–NRTI/integrase inhibitor similar to AZT Adverse effects Life-threatening allergic reactions–fever, dyspnea, rashes, intraoral blistering, nausea, headache. See AIDS, Nucleoside reverse transcriptase inhibitor, Reverse transcriptase.

abacavir

A nucleoside reverse transcriptase inhibitor drug used in combination with other anti-HIV drugs to treat AIDS. A brand name is Ziagen. In combination with lamivudine and zidovodine it is marketed as Trizivir.
References in periodicals archive ?
Following a hypersensitivity reaction to abacavir, NEVER restart Triumeq or any other abacavir-containing product.
Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV-1) and have discontinued lamivudine, a component of Triumeq.
Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with Triumeq is recommended in patients with underlying hepatic disease such as hepatitis B or C.
Discontinue Triumeq as medically appropriate and consider dose reduction or discontinuation of interferon alfa, ribavirin, or both.
Today's approval of Triumeq is the European regulatory authorisation to market the medicine in each member state of the European Union.
The US Food and Drug Administration (FDA) approved Triumeq on 22 August 2014.
Tivicay and Triumeq are registered trademarks of the ViiV Healthcare group of companies.
Safety Information for Triumeq in the European Union: [sup.
Dr Dominique Limet, Chief Executive Officer, ViiV Healthcare, said: "Today's approval of Triumeq offers many people living with HIV in the US the first single-pill regimen containing dolutegravir.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion on the Marketing Authorisation Application (MAA) for Triumeq on 26 June 2014.
Important Safety Information (ISI) for Triumeq (abacavir, dolutegravir and lamivudine) tablets
Severe acute exacerbations of hepatitis B have been reported in patients who are coCaeinfected with Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV-1) and have discontinued lamivudine, a component of Triumeq.